JP6063379B2 - 固形医薬組成物 - Google Patents

固形医薬組成物 Download PDF

Info

Publication number
JP6063379B2
JP6063379B2 JP2013511052A JP2013511052A JP6063379B2 JP 6063379 B2 JP6063379 B2 JP 6063379B2 JP 2013511052 A JP2013511052 A JP 2013511052A JP 2013511052 A JP2013511052 A JP 2013511052A JP 6063379 B2 JP6063379 B2 JP 6063379B2
Authority
JP
Japan
Prior art keywords
crystal
proline
benzothien
glucitol
anhydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013511052A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012144592A1 (ja
Inventor
啓介 坂浦
啓介 坂浦
田村　哲哉
哲哉 田村
片川　好史
好史 片川
迫　和博
和博 迫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kotobuki Seiyaku Co Ltd
Astellas Pharma Inc
Original Assignee
Kotobuki Seiyaku Co Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Seiyaku Co Ltd, Astellas Pharma Inc filed Critical Kotobuki Seiyaku Co Ltd
Publication of JPWO2012144592A1 publication Critical patent/JPWO2012144592A1/ja
Application granted granted Critical
Publication of JP6063379B2 publication Critical patent/JP6063379B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2013511052A 2011-04-22 2012-04-20 固形医薬組成物 Active JP6063379B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161478188P 2011-04-22 2011-04-22
US61/478,188 2011-04-22
PCT/JP2012/060701 WO2012144592A1 (ja) 2011-04-22 2012-04-20 固形医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2012144592A1 JPWO2012144592A1 (ja) 2014-07-28
JP6063379B2 true JP6063379B2 (ja) 2017-01-18

Family

ID=47041696

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511052A Active JP6063379B2 (ja) 2011-04-22 2012-04-20 固形医薬組成物

Country Status (4)

Country Link
JP (1) JP6063379B2 (ko)
KR (1) KR101841087B1 (ko)
CN (1) CN103687596B (ko)
WO (1) WO2012144592A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613579A (en) * 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
CN106924206A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 一种依格列净口服固体制剂及其制备方法
TWI795462B (zh) 2017-11-17 2023-03-11 日商鹽野義製藥股份有限公司 光安定性及溶出性優異的醫藥製劑
KR102097250B1 (ko) * 2019-11-09 2020-04-03 유니셀랩 주식회사 신규한 이프라글리플로진의 결정형, 이의 제조방법 또는 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5441386A (en) * 1977-09-02 1979-04-02 Kyowa Hakko Kogyo Co Ltd Preparation of l-proline by fermentation
WO2004080990A1 (ja) * 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
JP2006514044A (ja) * 2002-12-19 2006-04-27 アキュスフィア， インコーポレイテッド 脱凝集微粒子を含む医薬製剤を製造する方法
WO2007114475A1 (ja) * 2006-04-05 2007-10-11 Astellas Pharma Inc. Ｃ－グリコシド誘導体とｌ－プロリンとの共結晶
WO2009096455A1 (ja) * 2008-01-31 2009-08-06 Astellas Pharma Inc. 脂肪性肝疾患の治療用医薬組成物
JP2010536734A (ja) * 2007-08-16 2010-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐｉｖ阻害剤と併用するｓｇｌｔ２阻害剤を含む医薬組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4759102B2 (ja) 2009-10-23 2011-08-31 アステラス製薬株式会社 経口投与用医薬組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5441386A (en) * 1977-09-02 1979-04-02 Kyowa Hakko Kogyo Co Ltd Preparation of l-proline by fermentation
JP2006514044A (ja) * 2002-12-19 2006-04-27 アキュスフィア， インコーポレイテッド 脱凝集微粒子を含む医薬製剤を製造する方法
WO2004080990A1 (ja) * 2003-03-14 2004-09-23 Astellas Pharma Inc. Ｃ－グリコシド誘導体又はその塩
WO2007114475A1 (ja) * 2006-04-05 2007-10-11 Astellas Pharma Inc. Ｃ－グリコシド誘導体とｌ－プロリンとの共結晶
JP2010536734A (ja) * 2007-08-16 2010-12-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐｉｖ阻害剤と併用するｓｇｌｔ２阻害剤を含む医薬組成物
WO2009096455A1 (ja) * 2008-01-31 2009-08-06 Astellas Pharma Inc. 脂肪性肝疾患の治療用医薬組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6012036655; 医薬品添加物辞典 , 1994, ｐ．９３， １００-１０１, 株式会社薬事日報社 *
JPN6012036659; 薬剤学マニュアル , 1989, ｐ．８８， ８９， １１２， １１３, 株式会社南山堂 *

Also Published As

Publication number Publication date
CN103687596A (zh) 2014-03-26
WO2012144592A1 (ja) 2012-10-26
KR101841087B1 (ko) 2018-03-23
CN103687596B (zh) 2016-08-17
JPWO2012144592A1 (ja) 2014-07-28
KR20140022002A (ko) 2014-02-21

Similar Documents

Publication Publication Date Title
JP5859712B1 (ja) ４環性化合物を高用量含有する製剤
JP7096164B2 (ja) ジアミン誘導体を含む口腔内崩壊錠
JP6063379B2 (ja) 固形医薬組成物
JP4759102B2 (ja) 経口投与用医薬組成物
JP6455611B2 (ja) 経口投与用医薬組成物
JP5381978B2 (ja) アミド誘導体含有医薬組成物
TW200922546A (en) Galenical formulations of organic compounds
KR20190007896A (ko) 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 포함하는 구강 붕해정 및 이의 제조방법
JP6123795B2 (ja) 放出制御医薬組成物
JP6116847B2 (ja) シクロデキストリンとの混合体を含有する錠剤
JP2020196713A (ja) エドキサバンを含有する口腔内崩壊錠
JP5900702B2 (ja) 経口投与用医薬組成物
WO2016059192A1 (en) Composition comprising odanacatib

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160614

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161216

R150 Certificate of patent or registration of utility model

Ref document number: 6063379

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250